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Background: Both chronic hypoxia and allergic inflammation induce vascular remodeling in the lung, but only
chronic hypoxia appears to cause PH. We investigate the nature of the vascular remodeling and the expression and
role of hypoxia-induced mitogenic factor (HIMF/FIZZ1/RELMα) in explaining this differential response.
Methods: We induced pulmonary vascular remodeling through either chronic hypoxia or antigen sensitization and
challenge. Mice were evaluated for markers of PH and pulmonary vascular remodeling throughout the lung
vascular bed as well as HIMF expression and genomic analysis of whole lung.
Results: Chronic hypoxia increased both mean pulmonary artery pressure (mPAP) and right ventricular (RV)
hypertrophy; these changes were associated with increased muscularization and thickening of small pulmonary
vessels throughout the lung vascular bed. Allergic inflammation, by contrast, had minimal effect on mPAP and
produced no RV hypertrophy. Only peribronchial vessels were significantly thickened, and vessels within the lung
periphery did not become muscularized. Genomic analysis revealed that HIMF was the most consistently
upregulated gene in the lungs following both chronic hypoxia and antigen challenge. HIMF was upregulated in the
airway epithelial and inflammatory cells in both models, but only chronic hypoxia induced HIMF upregulation in
vascular tissue.
Conclusions: The results show that pulmonary vascular remodeling in mice induced by chronic hypoxia or antigen
challenge is associated with marked increases in HIMF expression. The lack of HIMF expression in the vasculature of
the lung and no vascular remodeling in the peripheral resistance vessels of the lung is likely to account for the
failure to develop PH in the allergic inflammation model.
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Pulmonary hypertension (PH) is clinically defined by a
mean pulmonary artery pressure (mPAP) ≥ 25 mmHg at
rest [1,2]. This condition can manifest itself as a primary
disease (idiopathic with or without a genetic linkage) or
as a complication of another disease such as collagen
vascular disease (e.g., scleroderma), human immunodefi-
ciency virus (HIV) infection, Shistosoma mansoni
(S. mansoni) infection, or chronic obstructive pulmonary
disease [1-4]. The exact initiating event in the pathoge-
nesis of PH is largely unknown, but several conditions,
including chronic hypoxia and chronic pulmonary
inflammation, have been associated with the develop-
ment of PH in humans [5-7]. These conditions induce
endothelial cell dysfunction as well as endothelial and
vascular smooth muscle cell proliferation and hyper-
trophy within the pulmonary circulation [8]; changes in
the cells of the vasculature thicken pulmonary arteries
and arterioles, narrowing their lumens, resulting in
increases in pulmonary vascular pressure and resistance
[5,8,9].
A growing body of evidence suggests that inflamma-
tion plays a role in the vascular remodeling associated
with chronic hypoxia and other experimental manifesta-
tions of PH [10-14]; these findings have accelerated
investigation into the potential mechanisms of inflam-
mation in this disease process [7]. Burke et al. [11]
reported the upregulation of several pro-inflammatory
genes in the lungs, including stromal cell-derived factor-
1 (SDF-1/CXCL12), monocyte chemoattractant protein-
1 (MCP-1), and interleukin (IL)-6, as well as the
accumulation of monocytes within the pulmonary vascu-
lature during chronic hypoxia. Also, many studies have
shown that T-cell helper 2 (Th2) cytokines, particularly
IL-4 and IL-13, are involved in the pathogenesis of pul-
monary vascular remodeling [13-18]. We have recently
reported that IL-4 acts as a proangiogenic molecule in
the lungs of mice during chronic hypoxia [13]. To exa-
mine the role of Th2 cytokines in pulmonary vascular
remodeling, Daley et al. [15] modified the standard
antigen-challenge model normally used to examine
inflammatory asthma. In this modified model, extended
antigen challenges with either ovalbumin (Ova) or
Aspergillus fumigatus antigen (Asp ag) lacking any viable
fungus produced severe pulmonary vascular remodeling
involving the proliferation of vascular smooth muscle
cells. This remodeling was reduced in both IL-4 knock-
out mice and mice that had IL-13 signaling neutralized
[15]. Surprisingly, this model produced no increases in
right ventricular systolic pressure. In an S. mansoni
infection model of PH, Graham et al. [19] demonstrated
that mice that lacked the IL-13 decoy receptor,
IL-13Rα2, displayed more severe pulmonary vascular
remodeling than did wild-type controls. They alsoreported an increase in right ventricle (RV) maximum
pressure in the infected IL13Rα2 knockout mouse
compared to uninfected wild-type controls. In a separate
study, Swain et al. [17] reported pulmonary vascular
remodeling and development of PH as a result of
Pneumocystis pneumonia in both wild-type and CD4+
T-cell-depleted mice; notably, these pathological changes
still occurred in IL-4 knockout mice, and IL-13 was not
detected in the lungs of the mice during the persistent
phase of the model [17]. These studies suggest a role for
inflammation in pulmonary vascular remodeling, but
currently, the exact involvement in this process is
unclear.
Hypoxia-induced mitogenic factor (HIMF), also known
as “found in inflammatory zone 1” (FIZZ1) or “resistin-
like molecule alpha” (RELMα), is highly upregulated in
the lung in response to both chronic hypoxia [10,20,21]
and Th2-mediated inflammation [16,17,22-27]. We have
demonstrated that HIMF has proliferative, angiogenic,
vasoconstrictive, and chemokine-like properties that are
associated with the development of PH [10,20,21,28,29].
We have also demonstrated that overexpression of
HIMF within the lungs induces a pattern of vascular
remodeling and hemodynamic changes similar to that in
chronic hypoxia-induced PH and that the in vivo block-
ade of HIMF expression within the lung reduces the
pathologic vascular and hemodynamic changes asso-
ciated with this model [10,20]. These data indicate that
HIMF plays a direct role in the induction of pulmonary
vascular remodeling and the development of PH
associated with chronic hypoxia. HIMF is also upregu-
lated in response to pulmonary inflammation [16,17,
22-25,27,30]. It has been reported that HIMF expression
is increased in the lungs of several models of
Th2-dependent inflammation, including allergic asthma
[15,22,23,27], human herpes virus 8 infection [25],
Pneumocystis pneumonia [17], S. mansoni infection
[16,19], and bleomycin-induced pulmonary fibrosis
[24,30]; all of these models are associated with pulmon-
ary vascular remodeling. Our laboratory has demon-
strated that a tail vein injection of recombinant murine
HIMF into mice induces a pro-inflammatory state within
the lungs associated with vascular remodeling [14] and
that HIMF can induce de novo production of both
SDF-1 and MCP-1 in cultured endothelial cells and
ex vivo lung organ culture [14,29]. We have also shown
that the human isoform of HIMF, RELMβ, is upregu-
lated in the lungs of patients diagnosed with
scleroderma-associated PH [31]. In lung samples from
these patients, RELMβ was expressed in inflammatory
cells (macrophages, T-cells) as well as in myofibroblasts,
endothelium, and vascular smooth muscle [31].
Renigunta et al. [32] also demonstrated that hypoxia
could induce human RELMβ expression in both a lung
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smooth muscle cells in vitro.
At the current time, it remains unclear whether Th2
models of vascular remodeling induction, including Ova,
Asp ag, and S. mansoni infection, actually cause the
development of PH as chronic hypoxia does (e.g. increased
mPAP, RV hypertrophy, vascular remodeling). In the
current study, we directly compare chronic hypoxia-
and Th2 inflammation-induced pulmonary vascular re-
modeling to address this issue and identify possible
explanations of the observed differences.
Methods
Experimental animals
Adult male C57BL/6 mice (6–8 weeks old; Charles River
Laboratories, Wilmington, MA) were used for all of the
studies. The animal housing and experimental protocols
were approved by the Animal Care and Use Committee
of the Johns Hopkins University. The mice had free
access to food and water and were housed in a room
with a 12:12 h light–dark cycle at 20–24°C.
Ova model of Th2-induced pulmonary vascular
remodeling
The Ova used for this study was prepared as follows:
Ova (Grade V; Sigma-Aldrich, St. Louis, MO) was
diluted to 1 mg/ml in 0.15 M sterile saline that was
complexed with Alum (Imject Alum; Thermo Fisher
Scientific, Waltham, MA). Mice were injected i.p. with
50 μg Ova and 2 mg Alum or equivalent volume of
sterile saline solution on day 0 of the experiment. This
procedure was then repeated on day 14. On days 28–30,
the mice were intranasally challenged with 50 μg Ova
diluted in 50 μl of saline or with 50 μl saline alone. The
intranasal challenges were also repeated on days 35–37,
41–43, and 45. Mice were sacrificed on day 46 of the
experiment by isoflurane overdose, and tissue was
processed as we have described [10,20]. Mice used for
hemodynamic measurement were anesthetized with
an i.p. injection of ketamine (100 mg/kg) and xylazine
(10 mg/kg), and mPAP was determined as described
[20,21]. All mice were euthanized by exsanguination.
Bronchoalveolar lavage fluid (BALF) was collected by
injecting the airways with 0.8 ml of sterile saline solution
under constant pressure via a 22-gauge catheter inserted
into the trachea followed by removal under constant pres-
sure. The BALF was centrifuged to remove cells and cell
particles; the supernatant was stored at −80°C for use in
Western blotting. The heart and lungs from each mouse
were removed en bloc. The right lung was tied off, and
the left lung was inflated with 1% low-melt agarose in
PBS with constant pressure (25 cm H2O) and placed on
ice as we have described previously [10,20]. The right
lung was removed and frozen in liquid nitrogen andstored at −80°C for use in Western blotting. The heart
was then removed and the agarose-inflated left lung was
placed in 10% neutral buffered formalin (Thermo Fisher
Scientific) at 4°C for 48–72 h. Following fixation, the
left lung was processed for paraffin embedding. The
heart was then dissected into the RV and left ven-
tricle plus septum (LV+S). Both portions of the heart
were then weighed and the RV and LV+S ratio deter-
mined [RV/(LV+S)].
Asp ag model of Th2-induced pulmonary vascular
remodeling
Asp ag that did not contain any viable fungus (GREER
Laboratories, Inc., Lenoir, NC) was diluted to 1 mg/ml
in sterile saline. Mice were injected i.p. with 100 μl of
this solution on days 0 and 14 of this experiment. On
days 28–30, the mice were intranasally challenged with
100 μg Asp ag diluted in 50 μl of saline or with 50 μl sa-
line alone. The intranasal challenges were also repeated
on days 35–37, 41–43, and 45. On day 46, the mice were
sacrificed and processed as stated above.
Chronic hypoxia model of pulmonary vascular
remodeling
Mice were exposed to normal room air (20.8% O2) or
10.0% O2 for 4 or 28 days as we have described
[10,20,21,33-36]. The mice were housed in Plexiglas
hypoxia chambers that had continuous air flow. The
fractional concentration of O2 was monitored and con-
trolled with a Pro:Ox model 350 unit (Biospherix,
Redfield, NY) by infusion of N2 (Roberts Oxygen;
Rockville, MD) balanced against an inward leak of air
through holes in the chamber. CO2 and ammonia were
scavenged throughout the experiment. At each time point,
the mice were sacrificed and processed as stated above.
Assessment of pulmonary vascular remodeling
Pulmonary vascular remodeling was assessed in a
blinded fashion as we have previously described
[10,20,33-36]. For our initial evaluation, lung sections
were stained with hematoxylin and eosin. To evaluate
the muscularization of pulmonary vessels, we dual
stained additional lung sections for von Willebrand
Factor (endothelium) and α-smooth muscle actin
(vascular smooth muscle) as we have previously
described [10,20,35,36]. We then examined approxi-
mately 100 randomly selected peripheral vessels
(<80 μm in diameter) from each mouse (n ≥ 3 for each
experimental group) under an Olympus-BHS micro-
scope attached to a QImaging Retiga 4000RV digital
camera. These vessels were classified as non-muscular
(NM), partially muscular (PM), or fully muscular (FM)
and analyzed as we have published [10,20]. Vascular
remodeling was also evaluated by the percent of medial
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[20,33]. Briefly, %MT was determined on the murine
lung sections receiving Movat pentachrome stain and
calculated as follows: %MT = [(external diameter –
internal diameter)/external diameter] × 100. For these
studies, we evaluated vessels that had an external diam-
eter between 25 and 150 μm. Approximately 30 vessels
in 30 consecutive fields were evaluated per lung.
Pulmonary vessels were classified as either peribronchial
or intra-alveolar. MetaMorph software (Molecular
Devices, Downingtown, PA) was used to make the
measurements.
Western blot analysis
Frozen mouse lung tissue was homogenized on ice with
a Brinkman Homogenizer (Polytron, Westbury, NY) in
homogenization/lysis buffer and the resultant protein
assayed as we have described [20]. The lung and BALF
samples were resolved by a 4–20% SDS-PAGE (Bio-Rad,
Hercules, CA) gel and transferred onto nitrocellulose
(Bio-Rad) membranes. The membranes were blocked
with 5% milk in Tris-buffered saline with 0.1% Tween 20
(TBS-T) for 1 h and then incubated with polyclonal goat
anti-mouse RELMα (1:500; R&D Systems, Minneapolis,
MN) antibodies in 5% milk/TBS-T overnight at 4°C. The
blots were then incubated in rabbit anti-goat IgG anti-
bodies (1:5000; Bio-Rad) conjugated to horseradish per-
oxidase in 5% milk/TBS-T for 1h at room temperature.
Enhanced chemiluminescence (Amersham, Piscataway,
NJ) was used to develop the blots followed by exposure
to X-ray film (Denville Scientific, Metuchen, NJ). To en-
sure equal loading and transfer, blots were stripped with
Blot Restore Membrane Rejuvenation Kit (Millipore)
and reprobed with murine anti-β actin (Santa Cruz
Biotechnology, Santa Cruz, CA).
Immunohistochemistry
Paraffin blocks of murine lungs exposed to saline chal-
lenge, Ova challenge, normoxia (20.8% O2), or hypoxia
(10.0% O2) were cut into 6-μm sections and placed on
clean positively charged glass slides. We deparaffinized,
rehydrated, and performed antigen retrieval on the slides
as described [10,20]. Endogenous peroxidases, avidin,
and biotin were blocked as described [10,20]. Nonspeci-
fic protein binding was blocked by incubating the
sections in normal rabbit serum for 1 h at room
temperature. Then, the sections were treated with poly-
clonal goat anti-mouse RELMα (1:200; R&D Systems,
Minneapolis, MN) antibodies or antibody diluent alone
overnight at 4°C. After being washed with PBS, the slides
were treated with rabbit anti-goat biotinylated secondary
antibodies and then an ABC horseradish peroxidase
reagent (Vectastain Elite ABC Kit; Vector Laboratories)
for 30 min each at room temperature. The HIMF signalwas developed with the Peroxidase Substrate Kit DAB
(Vector Laboratories), counterstained with hematoxylin,
dehydrated, and mounted as we have described [10,20].
The signal was visualized with an Olympus-BHS micro-
scope attached to a QImaging Retiga 4000RV digital
camera. Images were captured with ImagePro Plus
(version 5.1) software.
Immunofluorescence microscopy
Paraffin-embedded murine lung tissue was sectioned,
deparaffinized, and rehydrated; antigen retrieval was
performed as described under Immunochemistry. The
slides were then washed with PBS, and nonspecific
protein binding was blocked by incubating the sections
in normal horse serum for 1 h at room temperature.
The sections were then treated with polyclonal rabbit
anti-mouse RELMα (1:200; Abcam, Cambridge, MA)
and mouse anti-α-smooth muscle actin (1:500), rat anti-
F4/80 (1:100; Serotec, Raleigh, NC), mouse anti-CD3
(1:200; Santa Cruz Biotechnology), rat anti-major basic
protein (MBP; 1:500; Santa Cruz Biotechnology), rat
anti-neutrophil (NIMP-R14; 1:100; Abcam), rat anti-
CD19 (1:200; Abcam), or diluents alone overnight at
4°C. Next, the sections were incubated with DyLight 488-
labeled goat anti-rabbit IgG (H+L) (1:200; Jackson Immu-
noResearch Labs, Inc., West Grove, PA) and either
DyLight 594-labeled donkey anti-mouse IgG (H+L)
(1:200; Jackson ImmunoResearch Labs, Inc.) or DyLight
594-labeled donkey anti-rat IgG (H+L) (1:200; Jackson
ImmunoResearch Labs, Inc.) for 45 min at room
temperature in the dark. Finally, the sections were
washed in PBS, mounted with Vectashield Hardset
Mounting Media with 4’,6’-diamidino-2-phenylindole
dilactate (DAPI; Vector Laboratories), covered with a
glass coverslip, and visualized with an Olympus-BHS
microscope attached to a QImaging Retiga 4000RV
digital camera. Images were captured by using Image-
Pro Plus (version 5.1) software and colorized with
Adobe Photoshop CS5 software (Adobe Systems, Inc.,
San Jose, CA).
Genomic analysis
RNA was extracted from lung tissue with the Trizol
Reagent method (Invitrogen, Carlsbad, CA). Additional
purification was performed on RNAeasy columns
(Qiagen, Valencia, CA). The quality of total RNA sam-
ples was assessed by using an Agilent 2100 Bioanalyzer
(Agilent Technologies, Palo Alto, CA). The RNA sam-
ples were labeled according to the chip manufacturer’s
recommended protocols. Briefly, 0.5 μg of total RNA
from each sample was labeled by using the Illumina
TotalPrep RNA Amplification Kit (Ambion, Austin, TX)
in a two-step process of cDNA synthesis followed by
in vitro RNA transcription. Single stranded RNA (cRNA)
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UTP (Roche Diagnostics GmbH, Mannheim, Germany).
Seven hundred fifty nanograms of biotin-labeled cRNA
was hybridized for 16 h to Illumina Sentrix Mouse
Ref8_v1.1 BeadChips (Illumina, San Diego, CA). The
hybridized biotinylated cRNA was detected with
streptavidin-Cy3 and quantified by using Illumina’s
BeadStation 500GX Genetic Analysis Systems scanner.
Preliminary analysis of the scanned data was performed
with Illumina BeadStudio software, which returns single
intensity data values/gene following the computation of
a trimmed mean average for each probe type repre-
sented by a variable number of bead probes/gene on the
array. Z-transformation for normalization was per-
formed on each Illumina sample/array on a stand-alone
basis [37], and significant changes in gene expression
between class pairs were calculated by Z test [38]. Sig-
nificant gene lists were calculated by selecting genes that
satisfied a significance threshold criteria of Z test P
values ≤ 0.001, a false discovery rate ≤ 0.1 [39], and a
fold change ± 1.5 or greater. Changes in gene expression
across multiple groups were tested for by one-way
ANOVA. Gene expression signatures robustly identified
on the basis of statistical significance were tested against
multiple sample datasets by using a systematic gene set
analytical approach such as Parametric Analysis of Gene







Figure 1 Chronic hypoxia- and antigen-induced pulmonary vascular r
days, 20.8% O2), hypoxic (28 days, 10.0% O2), saline-challenged, and ovalbu
hematoxylin and eosin. Arrows: pulmonary vessels. Aw: airway. Scale bar: 5
normoxia, hypoxia, saline challenge, and Ova challenge. (C) Ratio of right v
[RV/(LV+S)] in mice exposed to normoxia, hypoxia, saline challenge, Ova ch
are shown as means ± SEM. The number of mice studied is indicated withAnalysis [41]. Differential regulation of related gene
expression signatures were quantified and compared by
using Gene Set Matrix Analysis [42], a modification of
the PAGE method in which multiple gene lists were
automatically tested against one or more datasets for
parametric enrichment (using the log ratios of calculated
changes in gene expression for the entire dataset).
Statistical analysis
Experimental values are expressed as means ± standard
error of the mean (SEM). A paired Student’s t-test was
used to compare the mean responses between two
groups. ANOVA was used to compare the mean
responses between experimental and control groups for
experiments containing multiple groups. The Tukey
multiple comparison test was used to determine between
which groups significant differences existed. A P value
of <0.05 was considered statistically significant.
Results
Induction of pulmonary vascular remodeling by chronic
hypoxia and Th2 inflammation
Mice exposed to chronic hypoxia exhibited increased
muscularization and thickening of the pulmonary vascu-
lature as well as mild inflammation, when compared to
normoxic controls (Figure 1A). The Ova-challenged
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emodeling. (A) Paraffin-embedded lung sections from normoxic (28
min (Ova)-challenged mice were rehydrated and stained with
0 μm. (B) Mean pulmonary artery pressure (mPAP) in mice exposed to
entricular (RV) weight to left ventricular plus septum (LV+S) weight
allenge, and Aspergillus fumingatus antigen (Asp ag) challenge. Data
in each bar. **P<0.01, ***P<0.001 versus control.
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cells surrounded and invaded the adventitia of the
remodeling blood vessels. Mice challenged with Asp ag
displayed a similar pattern of vascular remodeling and
inflammation to that of Ova-challenged mice (data not
shown). Saline-challenged mice displayed normal pul-
monary histology (Figure 1A).
Effect of chronic hypoxia and Th2 inflammation on
indicators of PH
Mice exposed to chronic hypoxia for 28 days had an
elevated mPAP (~1.75-fold) compared to normoxic con-
trols (hypoxia: 30.29 ± 1.44 mmHg vs. normoxia: 17.23 ±
0.57 mmHg; P<0.001; Figure 1B). Further analysis revealed
that animals exposed to hypoxia had a ~2.1-fold in-
crease in RV/(LV+S) ratio (0.407 ± 0.050) compared to
normoxic controls (0.192 ± 0.018; Figure 1C). In a
separate experiment, mice that were challenged with
intranasal Ova exhibited a slight (~1.3-fold) increase in
mPAP compared to mice challenged with saline (Ova
challenge: 22.65 ± 0.37 mmHg vs. saline: 17.88 ± 0.94
mmHg; P<0.01; Figure 1B). Even though mPAPA
HNormoxia
Saline
Figure 2 Evaluation of chronic hypoxia- and antigen-induced muscula
sections from normoxic (28 days, 20.8% O2), hypoxic (28 days, 10.0% O2), sa
rehydrated and double-stained with antibodies to von Willebrand factor (b
with hematoxylin (blue). Scale bar: 50 μm. (B-D) Percent muscularization of
PM, partially muscularized (C); FM, fully muscularized. n ≥ 3 mice for each g
increased versus control at P<0.05.increased slightly in the Ova-challenged mice, there
were no changes in RV/(LV+S) ratio when compared
to saline-challenged controls (Ova challenge: 0.216 ±
0.025; saline: 0.200 ± 0.013; Figure 1C). Asp ag chal-
lenge also failed to produce a change in RV/(LV+S)
ratio (0.198 ± 0.012; Figure 1C).
Evaluation of chronic hypoxia- and Th2 inflammation-
induced pulmonary vascular remodeling
In mice exposed to chronic hypoxia, muscularization of
the small pulmonary vessels was increased over the
course of the experiment (Figure 2). After exposure to
10.0% O2 for 28 days, the percentage of FM vessels was
increased (27.76 ± 4.48% vs. 8.25 ± 3.37%; P<0.05;
Figure 2D), while the percentage of NM vessels
decreased (31.58 ± 5.49% vs. 64.00 ± 12.28%; P<0.05)
compared to control animals exposed to normoxia
(Figure 2B). Examination of the lung sections from Ova-
challenged mice revealed no significant increases in new
muscularization (Figure 2B–D). Similar results were
observed following Asp ag challenge (NM: 46.72 ±
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to chronic hypoxia and Ova challenge is shown in
Figure 2A.
The %MT of pulmonary vessels was increased in mice
exposed to chronic hypoxia compared to that of normoxic
controls (Figure 3). Hypoxia increased the %MT of intra-
alveolar vessels from 16.67 ± 0.90% to 34.29 ± 1.60%
(Figure 3B) and of peribronchial vessels from 20.23 ± 2.36%
to 34.81 ± 1.60% (Figure 3C). Hypoxia increased the
thickness of both types of vessels in a similar fashion. Al-
though Ova-challenged mice did not display significant
new muscularization of small pulmonary arteries, these
challenges had a profound effect on hypertrophy/hyper-
plasia of the already muscularized peribronchial vessels
within the lung (Figure 3C). When vessels associated with
large airways were compared, %MT increased from 22.01
± 0.92% in saline controls to 34.53 ± 1.35% following Ova
challenge, increases very similar to those observed in pul-
monary vessels from hypoxia-exposed mice. Ova challenge
had virtually no effect on the %MT of intra-alveolar vessels
(Ova: 19.09 ± 0.77% vs. saline: 18.43 ± 0.58%; Figure 3B).
Genomic analysis of lung tissue
To determine if there were genes that were mutually regu-
lated by both chronic hypoxia and Th2 inflammation, we
performed genomic analysis of RNA isolated from lung tis-
sue from mice exposed to both models. In chronic hypoxiaA
Normoxia Hyp
Saline
Figure 3 Evaluation of chronic hypoxia- and Ova-induced increases in
(A) Paraffin-embedded lung sections from normoxic (28 days, 20.8% O2), hy
were rehydrated and stained with Movat’s pentachrome stain. Scale bar: 25
normoxia, hypoxia, saline challenge, and Ova challenge. Data are shown as
each bar. n ≥ 4 mice for each group. ***P<0.001 versus control.experiments, mice were exposed to either hypoxia (10.0%
O2) or room air (20.8% O2) for 4 days. To gain a more
complete look at pulmonary Th2 inflammation, we per-
formed genomic analysis on lung tissue from both Ova- and
Asp ag-challenged mice collected at the conclusion of these
experiments. Microarray analysis revealed that 36 transcripts
were significantly upregulated in all three murine models
(data not shown). Of those genes, ten were related to PH
and/or pulmonary injury (Figure 4). Interestingly, of these
ten transcripts, HIMF was the most consistently upregulated
in all experimental groups. Of the ten genes related to PH
and/or pulmonary injury, all could potentially be involved in
pulmonary vascular remodeling (Figure 4). One such gene
was chemokine (C-C motif) ligand 8 (Ccl8, also known as
MCP-2), which may be involved in the recruitment of in-
flammatory cells to the pulmonary vasculature (Table 1).
We also observed the upregulation of elastin, tenascin C, tis-
sue inhibitor of matrix metalloproteinase 1 (TIMP1), solute
carrier family 26, member 4 (Slc26a4), matrix metalloprotei-
nase 2 (MMP2), erythroid associated factor (ERAF), cathe-
psin K, and triggering receptor expressed on myeloid cells 2
(Trem2), which are known to be involved in tissue
remodeling (Table 1).
Evaluation of HIMF expression
Since HIMF was consistently upregulated in both
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Figure 4 Genomic analysis of lung tissue from mice exposed to chronic hypoxia and antigen challenge. Lung tissue samples from
normoxia (4 days, 20.8% O2, hypoxia (4 days, 10.0% O2), saline-challenged, Ova-challenged, and Asp ag-challenged mice were processed for cDNA
microanalysis. Data are displayed as the mean of the fold-increase versus simultaneous control (normoxia or saline-challenge). n ≥ 3 mice for
each group. HIMF: hypoxia-induced mitogenic factor; Ccl8: chemokine (C-C motif) ligand 8; TIMP1: tissue inhibitor of metalloproteinases 1;
Slc26a4: solute carrier family 26, member 4; MMP2: matrix metalloproteinase-2; ERAF: erythroid associated factor; Trem2: triggering receptor
expressed on myeloid cells 2.
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expression was increased in the BALF (Figure 5A) and
in whole lung lysates (Figure 5B) from mice exposed to
chronic hypoxia (4 days) or Ova challenge. Immunohis-
tochemical analysis of HIMF in these groups revealed
differential expression patterns in each (Figure 5C). In
chronic hypoxia, HIMF was expressed throughout the
lung and was upregulated in airway epithelium, alveolar
type II cells, vascular smooth muscle cells, endothelium,
and inflammatory cells. It was noticeably upregulated in
both peribronchial and intra-alveolar vessels. Ova chal-
lenge induced HIMF expression mainly in airway epithe-
lium and inflammatory cells; HIMF expression was
noticeably absent from vascular smooth muscle and endo-
thelium in all areas of the lungs of these mice (Figure 5C).
Cellular localization of HIMF
To determine which specific cell types in the lung ex-
press HIMF after chronic hypoxia or Ova challenge and
which inflammatory cells are recruited to the lung, we
performed immunofluorescence co-localization to com-
pare HIMF expression with the expression of cell-
specific markers. Similar to the immunochemistry
results, the lungs from mice exposed to chronic hypoxia
displayed HIMF-specific immunofluorescence in airwayepithelium, pulmonary vasculature, and inflammatory
cells; lungs from the Ova-challenged mice had increased
HIMF expression in airway epithelium and inflammatory
cells (Figures 6, 7, 8 and 9). More specifically, HIMF
signal co-localized with α-smooth muscle actin signal
following chronic hypoxia (Figure 6D). HIMF and α-
smooth muscle actin did not co-localize in the lung sec-
tions prepared from Ova-challenged mice (Figure 6H).
Interestingly, several HIMF-positive cells were located in
close proximity to the vasculature in both chronic hyp-
oxia and Ova challenge models. These HIMF-positive
cells were a mixture of macrophages (marker, F4/80;
Figure 7), neutrophils (marker, neutrophil marker;
Figure 8), and T-cells (marker, CD3; Figure 9). These
inflammatory cells were much more prominent around
the remodeling vasculature after Ova challenge than
after chronic hypoxia. Almost all of the remodeled ves-
sels in Ova-challenged mice were surrounded by a mix-
ture of these HIMF-expressing inflammatory cells, and
the overall number of inflammatory cells was large; only
a few vessels from the chronic hypoxia model had these
HIMF-expressing cells clustered around the vasculature,
and the overall number of inflammatory cells was
small following this stimulus. Further analysis revealed
that B-cells (marker, CD19) and eosinophils (marker, MBP)
Table 1 Commonly upregulated genes
Gene Potential function in PH References
HIMF endothelial cell proliferation [10,14,20,21,29]
smooth muscle cell proliferation
vasoconstriction
inflammation
Elastin tissue remodeling [43-45]
Tenascin C smooth muscle cell proliferation [46-49]
potential PH biomarker
Ccl8 inflammation [50]




MMP2 tissue remodeling [49,54]
potential PH biomarker
ERAF potential PH biomarker [55]
Cathepsin K tissue remodeling [56,57]
Trem2 inflammation [58]
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rounding vessels following Ova challenge, but these cells
did not express HIMF in our model system (data not
shown). Neither cell type was prominently present in the








Figure 5 Expression pattern of hypoxia-induced mitogenic factor (HIM
(A) Bronchioalveolar lavage fluid (BALF) and (B) whole-lung homogenates
challenged, and Ova-challenged mice were resolved by 4–20% SDS-PAGE a
anti-HIMF antibodies and developed using enhanced chemiluminescence.
reprobed with β-actin monoclonal antibodies. IB, immunoblot; IB*, immuno
normoxic, hypoxic, saline-challenged, and Ova-challenged mice were rehyd
Sections were counterstained with hematoxylin (blue). Aw: airway. Arrows:Discussion
The current study demonstrates that both chronic
hypoxia and repeated airway antigen challenges induce
pulmonary vascular remodeling in adult male C57BL/6
mice; however, differences were apparent in the types
and extent of remodeling. Exposure to chronic hypoxia
for 28 days increased all of the indicators of PH that we
examined in this study [mPAP, RV/(LV+S) ratio, vascular
remodeling]. In contrast to Ova-challenged mice, hyp-
oxic mice exhibited marked increases in both mPAP and
RV/(LV+S) ratio. In addition, mice exposed to chronic
hypoxia exhibited an overall neo-muscularization of the
pulmonary vessels throughout the entire lung in which
both intra-alveolar and peribronchial vessels were thick-
ened. The vessels from this model had the appearance of
concentric remodeling. At the 28-day time point, there
was little apparent perivascular inflammation. Several
recent reports have suggested that Th2 inflammation is
involved in the pulmonary vascular remodeling asso-
ciated with the development of PH [6,13,15-18,59];
therefore, we employed extended Ova-and Asp ag-
challenge models (3 challenges/week, 4 weeks) to ellicit
this response. Analysis of the parameters for PH
revealed a slight, but statistically significant increase in
mPAP (~1.3-fold) compared to saline control but no
change in RV/(LV+S) ratio compared to saline-







F) following chronic hypoxia or Ova challenge.
from normoxic (4 days, 20.8% O2), hypoxic (4 days, 10.0% O2), saline-
nd transferred to nitrocellulose. The blots were probed with rabbit
To confirm equal loading and transfer, the blots were stripped and
blot after stripping. (C) Paraffin-embedded lung sections from
rated and stained with antibodies raised against HIMF (brown).
small pulmonary vessels. Scale bar: 50 μm.
DAPI Mergeα-SMactinHIMF
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Figure 6 Co-localization of HIMF with pulmonary vascular smooth muscle. Paraffin-embedded lung sections from normoxic (4 days, 20.8% O2),
hypoxic (4 days, 10.0% O2), saline-challenged, and Ova-challenged mice were dual stained with rabbit anti-HIMF polyclonal antibody that was
visualized by DyLight 488-conjugated goat anti-rabbit IgG antibody (green; B, F), and mouse anti-α-smooth muscle actin monoclonal antibody
that was visualized by DyLight 594-conjugated donkey anti-mouse IgG antibody (red; C, G). Cell nuclei were counterstained with DAPI
(blue; A, E). The arrows in the merged images indicate co-localization of HIMF and α-smooth muscle actin (D, H). Scale bar: 50 μm.
Angelini et al. Respiratory Research 2013, 14:1 Page 10 of 16
http://respiratory-research.com/content/14/1/1challenges produced large amounts of pulmonary
inflammation, particularly around the peribronchial
vessels, but little new muscularization of peripheral pul-
monary vessels; specific analysis of the medial thickness






Figure 7 Co-localization of HIMF with macrophages. Paraffin-embedde
10.0% O2), saline-challenged, and Ova-challenged mice were dual stained w
DyLight 488-conjugated goat anti-rabbit IgG antibody (green; B, G), and ra
by DyLight 594-conjugated donkey anti-rat IgG antibody (red; C, H). Cell nu
merged images indicate co-localization of HIMF and F4/80 (D, I). Scale bar:extensive hypertrophy/hyperplasia in only the peribronchial
vessels. The remodeling that we observed in peribronchial
vessels looked very different from remodeled vessels in the
hypoxic mice; the vessels from Ova-challenged mice
appeared to have disorganized hypertrophy/hyperplasia.Merge4/80
D E
I J
d lung sections from normoxic (4 days, 20.8% O2), hypoxic (4 days,
ith rabbit anti-HIMF polyclonal antibody that was visualized by
t anti-F4/80 monoclonal antibody (macrophages) that was visualized
clei were counterstained with DAPI (blue; A, F). The arrows in the
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Figure 8 Co-localization of HIMF with neutrophils. Paraffin-embedded lung sections from normoxic (4 days, 20.8% O2), hypoxic (4 days, 10.0%
O2), saline-challenged, and Ova-challenged mice were dual stained with rabbit anti-HIMF polyclonal antibody that was visualized by DyLight 488-
conjugated goat anti-rabbit IgG antibody (green; B, G), and rat anti-neutrophil (NIMP-R14) monoclonal antibody (neutrophils) that was visualized
by DyLight 594-conjugated donkey anti-rat IgG antibody (red; C, H). Cell nuclei were counterstained with DAPI (blue; A, F). The arrows in the
merged images indicate co-localization of HIMF and neutrophil marker (NIMP-R14; D, I). Scale bar: 50 μm. (E, J) Merged images enlarged to show
co-localization.
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had the most HIMF-expressing inflammatory cells asso-
ciated with them.
Several Th2 inflammatory models of pulmonary vascu-
lar remodeling have been developed in recent years
(e.g., Ova-challenge, S. mansoni infection), but these






Figure 9 Co-localization of HIMF with T-cells. Paraffin-embedded lung s
saline-challenged, and Ova-challenged mice were dual stained with rabbit
conjugated goat anti-rabbit IgG antibody (green; B, G), and mouse anti-CD
donkey anti-mouse IgG antibody (red; C, H). Cell nuclei were counterstaine
localization of HIMF and CD3 (D, I). Scale bar: 50 μm. (E, J) Merged imagesPH. As opposed to chronic hypoxia, in which experi-
mental animals consistently display elevated pulmonary
and RV pressures, Th2 inflammatory models display
little or no pulmonary pressure change [15,19,60]. In the
current study, chronic hypoxia induced an almost two-
fold increase in both mPAP and RV/(LV+S). Although
we did observe a mild increase in the mPAP (~1.3-foldMergeD3
D E
I J
ections from normoxic (4 days, 20.8% O2), hypoxic (4 days, 10.0% O2),
anti-HIMF polyclonal antibody that was visualized by DyLight 488-
3 monoclonal antibody that was visualized by DyLight 594-conjugated
d with DAPI (blue; A, F). The arrows in the merged images indicate co-
enlarged to show co-localization.
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not accompanied by RV hypertrophy. Daley et al. [15]
reported no changes in right ventricular end systolic
pressure in association with antigen challenge. Crosby
et al. [60] reported extensive pulmonary vascular remo-
deling associated with a murine model of S. mansoni
infection, but these animals did not experience signifi-
cant PH; the authors did suggest that mPAP was higher
in those mice that had a greater and more widespread
egg burden. In another study on S. mansoni infection,
Graham et al. [19] also reported extensive remodeling,
but demonstrated significant RV pressure increases only
in IL-13Rα2 knockout mice, not in infected wild-type
mice. It is possible that elevated pulmonary pressures
were not observed in these models because of the time
frames used for these experiments. A follow-up study
performed by Crosby et al., [61], demonstrated that S.
mansoni infection induced pulmonary vascular remode-
ling, increased RV pressures, as well as RV hypertrophy
at 25 weeks following initial infection. These investiga-
tors also demonstrated that the severity of the vascular
remodeling correlated with the proximity of the S.
mansoni eggs. Another long-term study performed by
Mushaben et al., [62] demonstrated that chronic expo-
sure to house dust mite antigen induced pulmonary vas-
cular remodeling at 7 and 20 weeks of exposures. This
study also demonstrated increased RV pressures at 20
weeks, but not at 7 weeks. These studies suggest that it
may be possible that a chronic Th2 stimulus may be
required for the development of PH in these models.
Immunohistochemical expression patterns of HIMF
following either chronic hypoxia or Ova challenge
revealed a marked difference between these two models.
Most significant among these differences was the con-
sistent expression of HIMF in the vascular endothelium
and smooth muscle throughout the lung following
chronic hypoxia and the complete absence of HIMF
expression in the vasculature following Ova challenge.
Hypoxia induced HIMF staining in airway epithelial
cells, alveolar type II cells, endothelium, vascular smooth
muscle, and inflammatory cells, findings consistent with
data that we have previously reported in both mice and
rats [20,21] as well as human PH lung [31]. Using
double-labeling immunofluorescence microscopy, we
also showed that HIMF co-localizes with smooth muscle
cells only in the chronic hypoxia model. It is likely that a
hypoxic stimulus induces smooth muscle cells within
the lung to directly express HIMF, which could initiate
the vascular remodeling process. This finding is consist-
ent with our prior work in which we showed that knock-
down of HIMF reduced chronic hypoxia–induced
vascular remodeling [20]. We did observe that HIMF
was expressed in macrophages, T-cells, and neutrophils
during chronic hypoxia, but these co-localization eventsoccurred less consistently than did HIMF co-localization
with α-smooth muscle actin. After Ova challenge, HIMF
was exclusively expressed in airway epithelial cells and
inflammatory cells, a finding consistent with those of
previous studies that used Ova or Asp ag challenge
[15,23,27]. The initial study by Holcomb et al. [23]
demonstrated HIMF expression in alveolar type II cells
following aerosolized Ova challenge in adult female
BALB/c mice, but no expression in the vascular tissue.
The expression pattern of HIMF is very similar in
another Th2-dependent model of pulmonary vascular
remodeling. Following S. mansoni infection, HIMF is
also upregulated in areas surrounding the typical granu-
lomas, but not in the remodeled vessels themselves [19].
The lack of HIMF expression in the vascular tissue du-
ring inflammation-induced remodeling would suggest
that HIMF may be acting on the vasculature through an
indirect process. To examine this concept, we identified
the inflammatory cells that expressed HIMF after Ova
challenge. We found that HIMF was expressed by sev-
eral different inflammatory cell types, including macro-
phages, T-cells, and neutrophils, in Ova-challenged mice
and that very large numbers of such cells surrounded
the remodeling peribronchial blood vessels. The expres-
sion of HIMF by macrophages is consistent with previ-
ously reported data [23]. To the best of our knowledge,
this is the first study to demonstrate that HIMF is
expressed in neutrophils and T-cells at the site of in-
flammation within the lung. At the time point examined,
HIMF was not expressed in eosinophils or B-cells. It is
possible that HIMF is expressed by these cells [63] at a
different time point or in a different mouse strain than
those used for this study. We have previously demon-
strated that the human homolog to HIMF, RELMβ, is
expressed in macrophages and T-cells as well as in vas-
cular cells, plexiform lesions, and myofibroblasts, in
patients diagnosed with scleroderma-associated PH [31].
The time course of HIMF expression also differs fol-
lowing hypoxia and antigen challenge. During chronic
hypoxia, HIMF mRNA expression is maximal 24 h after
initial hypoxic exposure [21]; HIMF protein expression
peaks at 4 days of chronic hypoxia and gradually
decreases until it reaches baseline levels at approxi-
mately 14 days [21]. In the mouse model, the increased
HIMF expression correlates with the hyperplastic phase
of lung vascular remodeling. This is also consistent with
our observations that HIMF is upregulated in the vascu-
lar smooth muscle cells that are undergoing cell division
[proliferating cell nuclear antigen (PCNA)- and/or
Ki67-positive]. Other work from our laboratory supports
this hyperplastic role for HIMF, as we have found HIMF
to exert a marked shift in human mesenchymal cells to a
dividing phenotype [64]. Because HIMF is primarily
expressed during the early hyperplastic phase of chronic
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expression prevents long-term remodeling associated
with chronic hypoxia [20], we hypothesize that HIMF
acts as an initiating factor for pulmonary vascular
remodeling. Lack of HIMF protein within the lungs at
this early point of chronic hypoxia reduces the extensive
remodeling that would normally result [20]. With Ova
challenge, HIMF appears to be consistently upregulated
throughout the time period of the model, albeit focal to
the area of inflammation. Sun et al. [27] has reported
increased HIMF expression following an initial 7-day
Ova challenge. We and others have demonstrated exten-
sive HIMF expression following extended Ova challenges
(3 challenges/week, 4 weeks) [15,22,23,27].
It is currently unknown whether HIMF gene expres-
sion is regulated differently through hypoxia and Th2
stimulation or if changes in the two models are parallel.
Evidence from sequence analysis and other published
work suggests that the transcription factors CCAAT box
enhancer binding protein-β (C/EBPβ), hypoxia-inducible
factor-1α (HIF-1α), signal transducers and activators of
transcription-6 (STAT6), and/or NF-κB may be involved
in HIMF gene regulation [21,24,26,65-68]. Stutz et al.
[26] demonstrated that HIMF itself is activated by the
Th2 inflammatory pathway in cultured murine bone
marrow cells via IL-4 and IL-13 activation of STAT6
and/or C/EBPβ in its promoter region. Another previous
study demonstrated that bleomycin-induced pulmonary
HIMF mRNA expression was partially blocked in IL-4
and IL-13 knockout mice [24]. This same study also
demonstrated that combined knockout of IL-4 and
IL-13 completely blocked HIMF expression in the
bleomycin-injured lung. Also, the number of HIMF-
positive cells located around remodeled vessels in an
Asp ag-challenge model was reduced in IL-4 knockout
mice compared to that in wild-type controls [15]. In S.
mansoni infection, HIMF expression is at least partly
dependent on IL-13Rα1 [19]. Currently, not much is
known about hypoxia-induced regulation of HIMF. In a
recent study published by our laboratory, we demon-
strated hypoxia-induced HIMF expression in both IL-4
and STAT6 knockout mice [14]. This finding would sug-
gest that Th2 inflammation and hypoxia regulate HIMF
expression through different mechanisms. This possibi-
lity is consistent with both hypoxia-related and Th2-
related transcription factor binding sites in the regula-
tory regions of the HIMF gene.
We have previously shown that HIMF has mito-
genic, angiogenic, anti-apoptotic, vasoconstrictive, and
chemokine-like properties both in vivo and in vitro
[10,20,21,28,29,68]. These are key processes involved
in the pathogenesis of PH. We have demonstrated
that the addition of recombinant HIMF induces a
dose-dependent growth response of cultured pulmonaryvascular smooth muscle cells [21], and others have
shown that intratracheal instillation of HIMF induces
proliferation of pulmonary vascular smooth muscle
in vivo [69]. The addition of recombinant HIMF
in vitro activates the phosphoinositide 3-kinase (PI-3K)
as well as the extracellular signal-regulated kinase 1/2
(ERK1/2) signaling pathways [21,65-67,70-72], both of
which are key proliferative pathways. These signaling
events occur in isolated primary cultured rodent and
human pulmonary vascular smooth muscle cells, illus-
trating that HIMF acts directly on the cultured cells to
induce proliferation; this signaling appears to occur in-
dependently of any secondary inflammatory effects that
could be induced by HIMF. The differential expression
that we have observed may affect the pulmonary vascu-
lar remodeling that is observed in each model. It is pos-
sible that upregulation of HIMF in both vascular
smooth muscle and endothelium may contribute to an
autocrine pathway in which HIMF induces cell prolif-
eration within the vasculature. The overexpression of
HIMF in the lung vasculature appears to contribute to
the overall vascular remodeling of the lung that we are
seeing during chronic hypoxia. We have previously
shown that AAV-HIMF–induced overexpression of
HIMF in the pulmonary vasculature leads to prolifera-
tion of both vascular smooth muscle and endothelial
cells [20]. During Ova challenge, pulmonary vascular
remodeling is localized to the vessels associated with
large airways. In this model, large amounts of HIMF
are produced and secreted by airway epithelial and in-
flammatory cells, but no HIMF is expressed in the pul-
monary vasculature itself. It is reasonable to suggest
that the HIMF secreted into the surrounding areas of
the lung affects the local pulmonary vessels and thereby
drives the localized remodeling. Daley et al. [15]
reported that in an Asp ag-challenge model, HIMF was
expressed in areas surrounding remodeled vessels simi-
lar to what we have observed in our Ova-challenge
model. The smooth muscle cells in these remodeled
vessels also express the markers for cellular prolifera-
tion, Ki67 and PCNA [15].Conclusions
Our results demonstrate that pulmonary vascular re-
modeling in mice induced by chronic hypoxia or antigen
sensitization and challenge is associated with marked
increases in HIMF expression both at the message and
protein levels. HIMF was upregulated in the airway epi-
thelium and inflammatory cells in both models, although
it was expressed in the vascular smooth muscle of the
hypoxia model only. It is certainly possible that the ex-
pression of HIMF within the pulmonary vessels them-
selves may lead to more robust vascular remodeling;
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right heart hypertrophy. Taken together, our data suggest
that HIMF is a key factor in the etiology of both
hypoxia- and inflammation-induced models of pulmo-
nary vascular remodeling.
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